期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 27, 期 1, 页码 1-18出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-006-9060-0
关键词
anti-Tac; adult T-cell leukemia; daclizumab; IL-2 receptor; monoclonal antibody
类别
资金
- Intramural NIH HHS Funding Source: Medline
- NATIONAL CANCER INSTITUTE [Z01SC004002, ZIASC004002] Funding Source: NIH RePORTER
Twenty-five years ago, we reported the production of the monoclonal antibody, anti-Tac that identifies the IL-2 receptor alpha subunit and blocks the interaction of IL-2 with this growth factor receptor. In 1997, daclizumab (Zenapax((R))), the humanized form of this antibody, was approved by the FDA for use in the prevention of renal allograft rejection. In addition, we demonstrated that daclizumab is of value in the treatment of patients with noninfectious uveitis, multiple sclerosis, and the neurological disease human T-cell lymphotropic virus I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Others demonstrated therapeutic efficacy with daclizumab in patients with pure red cell aplasia, aplastic anemia, and psoriasis. Thus, translation of basic insights concerning the IL-2/IL-2 receptor system obtained using the monoclonal antibody daclizumab provided a useful strategy for the prevention of organ allograft rejection and the treatment of patients with select autoimmune diseases or T-cell leukemia/lymphoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据